RecruitingPhase 4NCT05858619
Molecular Signatures of Cutaneous Dupilumab Response
Sponsor
University of California, San Francisco
Enrollment
15 participants
Start Date
Feb 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- 18 years of age or older
- atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7
Exclusion Criteria3
- Known pregnancy
- Known immunodeficiencies
- Known parasitic infection -
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDupilumab
dupilumab 600 mg injection initially and then 300 mg every other week
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05858619
Related Trials
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT072629831 location
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT0700342545 locations
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT0729080343 locations
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT0727766050 locations
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT050422581 location